Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sensitizing Burkitt lymphoma to EBV-CTLs

Blood(2020)10.1182/blood.2020005492Source: DataRank Database

Sensitizing Burkitt lymphoma to EBV-CTLs is a research paper published in Blood (2020). On theSindex it has a DataRank of 0.516. It has been cited 7 times, with 7 citing works in its 1-hop citation network.

N/A

0.516DataRank · unranked

Scored on demand from live citation data

7 citations · 7 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.53)OA: greenTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 60%Citation Network 40%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.204

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis
Bioengineered20218 citations36 referencesContributes 0.061
Chemical Components of Polygonum cuspidatum Ethylacetate Subfraction and their Effects on Epstein-Barr Virus Lytic Genes Expression
Journal Of Biochemical Technology20224 citations27 referencesContributes 0.060
Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency
Frontiers in Immunology202319 citations53 referencesContributes 0.057
Topological implications of DNA tumor viral episomes
BMB Reports202210 citations69 referencesContributes 0.035
How Does Epstein–Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?
Frontiers in Cellular and Infection Microbiology202216 citations166 referencesContributes 0.017

Authors (1)

Helen E. Heslop ORCID

Live enrichment

PubMed:32437562 OpenAlex:https://openalex.org/W3026211455

NCI NIH HHS

Grant: P30 CA125123

NCI NIH HHS

Grant: P50 CA126752

FWCI

0.53

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

green

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7243150

publisherhttp://ashpublications.org/blood/article-pdf/135/21/1822/1731366/bloodbld2020005492c.pdf

journalhttps://doi.org/10.1182/blood.2020005492

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32437562

Fields of Study

Viral-associated cancers and disordersLymphoma Diagnosis and TreatmentCAR-T cell therapy researchBurkitt LymphomaEpigenesis, GeneticHerpesvirus 4, HumanHumansImmunotherapyLymphoma

MeSH Terms

Burkitt LymphomaHerpesvirus 4, HumanHumansImmunotherapyLymphomaEpigenesis, Genetic

Keywords

AntigenDecitabineLymphomaVirus latencyVirusEpstein–Barr virusVirologyMononucleosisImmunologyHerpesviridaeBiologyCancer researchMedicineViral diseaseDNA methylationViral replicationGene expression

Sustainable Development Goals

SDG 0: Good health and well-being

Sensitizing Burkitt lymphoma to EBV-CTLs

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (1)

Funding (2 grants)

Impact

Open Access

Topics